Welcome to the pages of the Serve lab!
We – a team of highly motivated and trained cell and molecular biologists, biochemists, physicians and clinician scientists - are particularly interested in uncovering targetable molecular mechanisms of clinically relevant biological phenotypes in Acute Myeloid Leukemia (AML) with the goal of discovering novel clues for AML therapy.
To do this, we are using state-of-the-art techniques, including forward genetic CRISPR/Cas9 dependency as well as resistance and sensitizer screens, CRISPR/Cas9-based prime editing to introduce patient-specific oncogene mutations and BH3 profiling to measure apoptotic priming and dependencies in AML cell lines and patient-derived AML blasts.
To do this, we are using state-of-the-art techniques, including forward genetic CRISPR/Cas9 dependency as well as resistance and sensitizer screens, CRISPR/Cas9-based prime editing to introduce patient-specific oncogene mutations and BH3 profiling to measure apoptotic priming and dependencies in AML cell lines and patient-derived AML blasts.
NEWS
NEWS
